Dorsomorphin dihydrochloride (Compound C dihydrochloride) 是一种有效,选择性和 ATP 竞争性的AMPK抑制剂,Ki为 109 nM。Dorsomorphin dihydrochloride 通过靶向抑制 I 型受体ALK2,ALK3和ALK6来抑制 BMP 途径。Dorsomorphin dihydrochloride 诱导自噬 (autophagy) 作用。
生物活性 | Dorsomorphin dihydrochloride (BML-275 dihydrochloride; Compound C dihydrochloride) is a potent, selective and ATP-competitiveAMPKinhibitor, with aKiof 109 nM[1]. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptorsALK2,ALK3, andALK6. Dorsomorphin dihydrochloride inducesautophagy[2]. |
IC50& Target[1][2] | AMPK 109 nM (Ki) | ACVR1 | BMPR1A | ALK6 | Autophagy |
|
体外研究 (In Vitro) | Dorsomorphin (compound C) (0-10 μM, 18 h) suppresses 2DG-induced GRP78 promoter activity in human fibrosarcoma HT1080 cells in a dose-dependent manner but has little effect on tunicamycin-induced GRP78 promoter activity. Dorsomorphin (compound C) C also suppresses GRP78 promoter activity induced by glucose withdrawal. Dorsomorphin (compound C) has no effect on 2DG-induced PERK activation and reduces the both basal and 2DG-induced AMPK phosphorylation levels in HT1080 cells[2].
Western Blot Analysis[2] Cell Line: | Human fibrosarcoma HT1080 cells. | Concentration: | 0-10 μM. | Incubation Time: | 18 hours | Result: | Suppressed 2DG-induced GRP78 promoter activity in a dose-dependent manner and also suppressed GRP78 promoter activity induced by glucose withdrawal. |
|
体内研究 (In Vivo) | Dorsomorphin (compound C: 10 mg/kg, intravenously once) treatment leads to a 60% increase in total serum iron concentrations, reduces basal levels of hepcidin expression and increasing serum iron concentrations in adult mice[3]. Dorsomorphin (compound C: 0.2 mg/kg, i.v., 30 min before LPS injection) reduces ICAM-1 and VCAM-1 expression in LPS-injected rat aorta[4]. Dorsomorphin (compound C; 25 mg/kg; i.p. injection, in male BALB/c mice) treatment before lipopolysaccharide (LPS) injection significantly reduces lethality in contrast to animals treated with LPS challenge only[5].
Animal Model: | Wild-type (WT) C57BL/6 adult mice that are fed a standard iron-replete diet express high levels of hepcidin[3]. | Dosage: | 10 mg/kg. | Administration: | Intravenously once. | Result: | Led to a 60% increase in total serum iron concentrations. Effective in reducing basal levels of hepcidin expression and increasing serum iron concentrations in adult mice. |
Animal Model: | Male Sprague-Dawley rats, 8 weeks of age (body weight 230-250 g)[4]. | Dosage: | 0.2 mg/kg. | Administration: | I.V., 30 min before LPS injection. | Result: | Reduced ICAM-1 and VCAM-1 expression in LPS-injected rat aorta. |
Animal Model: | Male BALB/c mice at 6-7 weeks of age weighing 20-22 g[5] | Dosage: | 25 mg/kg | Administration: | Injection i.p.; 60 min before LPS challenge | Result: | Treatment of mice with 25 mg/kg before LPS injection significantly reduced lethality in contrast to animals treated with LPS challenge only. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
溶解性数据 | In Vitro: H2O : 50 mg/mL(105.84 mM;Need ultrasonic) DMSO : 5 mg/mL(10.58 mM;Need ultrasonic) 配制储备液 1 mM | 2.1168 mL | 10.5840 mL | 21.1681 mL | 5 mM | 0.4234 mL | 2.1168 mL | 4.2336 mL | 10 mM | 0.2117 mL | 1.0584 mL | 2.1168 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: PBS Solubility: 20 mg/mL (42.34 mM); Clear solution; Need ultrasonic and warming and heat to 60℃
*以上所有助溶剂都可在本网站选购。 |